ASCO 2024 Poster for Trial #21-40

Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.

Wednesday, June 19, 2024

Dr. Douglas Orr

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 21-40

ASCO 2024 Poster for Trial 21-40

Click to view the ASCO 2024 Poster for Trial 21-40 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab

Dec 17, 2024

Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D) selection for Phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors

Dec 17, 2024

Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors

Dec 17, 2024
See All Posts